Western University

Scholarship@Western
Paediatrics Publications

Paediatrics Department

9-7-2018

Phosphorylation-dependent inhibition of Akt1
Nileeka Balasuriya
Schulich School of Medicine & Dentistry

McShane McKenna
Schulich School of Medicine & Dentistry

Xuguang Liu
Schulich School of Medicine & Dentistry

Shawn S.C. Li
Schulich School of Medicine & Dentistry, sli@uwo.ca

Patrick O’donoghue
Schulich School of Medicine & Dentistry

Follow this and additional works at: https://ir.lib.uwo.ca/paedpub

Citation of this paper:
Balasuriya, Nileeka; McKenna, McShane; Liu, Xuguang; Li, Shawn S.C.; and O’donoghue, Patrick,
"Phosphorylation-dependent inhibition of Akt1" (2018). Paediatrics Publications. 2331.
https://ir.lib.uwo.ca/paedpub/2331

G C A T
T A C G
G C A T

genes

Article

Phosphorylation-Dependent Inhibition of Akt1
Nileeka Balasuriya 1 , McShane McKenna 1 , Xuguang Liu 1 , Shawn S. C. Li 1
and Patrick O’Donoghue 1,2, *
1

2

*

Department of Biochemistry, Schulich School of Medicine and Dentistry, The University of Western Ontario,
London, ON N6A 5C1, Canada; bbalasur@uwo.ca (N.B.); mmcken22@uwo.ca (M.M.); xliu329@uwo.ca (X.L.);
sli@uwo.ca (S.S.C.L.)
Department of Chemistry, Faculty of Science, The University of Western Ontario,
London, ON N6A 5C1, Canada
Correspondence: patrick.odonoghue@uwo.ca; Tel.: +1-519-850-2373

Received: 20 July 2018; Accepted: 10 August 2018; Published: 7 September 2018




Abstract: Protein kinase B (Akt1) is a proto-oncogene that is overactive in most cancers.
Akt1 activation requires phosphorylation at Thr308; phosphorylation at Ser473 further enhances
catalytic activity. Akt1 activity is also regulated via interactions between the kinase domain
and the N-terminal auto-inhibitory pleckstrin homology (PH) domain. As it was previously
difficult to produce Akt1 in site-specific phosphorylated forms, the contribution of each activating
phosphorylation site to auto-inhibition was unknown. Using a combination of genetic code expansion
and in vivo enzymatic phosphorylation, we produced Akt1 variants containing programmed
phosphorylation to probe the interplay between Akt1 phosphorylation status and the auto-inhibitory
function of the PH domain. Deletion of the PH domain increased the enzyme activity for all
three phosphorylated Akt1 variants. For the doubly phosphorylated enzyme, deletion of the PH
domain relieved auto-inhibition by 295-fold. We next found that phosphorylation at Ser473 provided
resistance to chemical inhibition by Akti-1/2 inhibitor VIII. The Akti-1/2 inhibitor was most effective
against pAkt1T308 and showed four-fold decreased potency with Akt1 variants phosphorylated at
Ser473. The data highlight the need to design more potent Akt1 inhibitors that are effective against
the doubly phosphorylated and most pathogenic form of Akt1.
Keywords: genetic code expansion; protein kinase B; phosphoinositide dependent kinase 1;
phosphoseryl-tRNA synthetase; tRNASep

1. Introduction
Protein kinase B (Akt) is a human serine–threonine kinase and a member of the AGC family of
protein kinases [1,2]. The pathway regulated by Akt is the most commonly activated signaling pathway in
human cancers [3]. Given that more than 50% of human tumors contain hyperactivated Akt [2], effective
inhibition of active Akt has the potential to treat several distinct cancers. There are three AKT genes in
humans, encoding the isozymes Akt1, Akt2, and Akt3. The Akt1 isozyme has well-established roles in
many human cancers. Overactive Akt1 is a hallmark of diverse human malignancies [3,4] and linked to
reduced survival outcomes [5,6]. Indeed, Akt1 is as a leading drug target in cancer [7,8]. Over 300 clinical
trials have been completed or are under way that involve targeting the Akt1 signaling pathway [9,10].
Akt1 is a key regulator of the phosphoinositide 3 kinase (PI3K)/Akt1 signaling cascade
that controls cell growth and survival [1]. In human cells, the activation of Akt1 occurs
in response to growth factor stimulation. Following activation by a receptor tyrosine kinase
at the plasma membrane, PI3K phosphorylates its immediate downstream target, a lipid
second messenger called phosphatidylinositol-4,5-bisphosphate (PIP2 ), converting PIP2 into
phosphatidylinositol-3,4,5-triphosphate (PIP3 ) (Figure 2) [2]. Membrane-anchored PIP3 is a binding
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site for pleckstrin homology (PH) domain–containing proteins such as Akt1 and one of the upstream
kinases that activates Akt1, phosphoinositide-dependent kinase 1 (PDK1) [11]. Co-localization
of Akt1 with PDK1 leads to partial activation of Akt1 by PDK1-mediated phosphorylation of
Thr308 in the kinase domain of Akt1. Mechanistic target of rapamycin complex 2 (mTORC2) is
responsible for phosphorylating Akt1 at Ser473 in the C-terminal hydrophobic motif of Akt1 (Figure 2).
The phosphorylation of Ser473 further increases the kinase activity of Akt1. Although the cellular
role of Ser473 phosphorylation is not well defined, several studies point to the idea that pSer473 may
impact Akt1 substrate selectivity (reviewed in [2]).
Leveraging our ability to produce Akt1 protein in specifically phosphorylated forms (Figure 1),
we recently quantified the precise contribution of pThr308 and pSer473 to Akt1 activity in vitro
and in mammalian cells [12]. In studies with purified full-length Akt1, we found that pAkt1T308
achieves 30% of the activity of the doubly phosphorylated kinase. We also observed in COS-7
cells that pSer473 is dispensable for Akt1 signaling [12]. In close agreement with our findings,
studies in adipocytes found that half-maximal Akt1 cellular signaling activity is achieved when
the kinase is 5–22% phosphorylated [13]. In studies of human tumors [12–15] and in clinical diagnostic
settings [14,15], the phosphorylation status of Akt1 at Ser473 only is often used as a marker or proxy
for Akt1 activity. Our work [12] and work by others [16] found that phosphorylation of Thr308 alone
was sufficient for maximal Akt1 signal prorogation in cells. These results indicated that compared to
Ser473, Thr308 phosphorylation status is a superior biomarker for Akt1 activity.

Figure 1. Production of Akt1 variants with programmed phosphorylation. To produce pAkt1T308 ,
PDK1 (Akt1’s natural upstream kinase) was co-expressed along with Akt1. To produce pAkt1S473 ,
the phosphoserine orthogonal translation system was used to genetically incorporate phosphoserine
at position 473 in response to an amber (UAG) codon. The ppAkt1T308,S473 variant was produced by
combining both methods. WT: wild type.

The N-terminal PH domain is auto-inhibitory to Akt1 activity. Due to previous roadblocks
in preparing Akt1 with programmed phosphorylation(s), there are no reports that measure the
contribution of a phosphate at each key regulatory site to the auto-inhibition of Akt1 by the PH domain.
In the current model, Akt1 exists in an auto-inhibited (PH-in) and activated (PH-out) conformation.
In its auto-inhibited conformation (PH-in), the PH domain binds between the N- and C-terminal lobes
of the unphosphorylated Akt1 kinase domain. During growth factor–mediated activation of Akt1,
the PH domain forms a new interaction with PIP3 , causing it to move outward, away from the now
more accessible kinase domain. This PH-out conformation is readily activated via phosphorylation
at Thr308 by PDK1 and Ser473 by mTORC2. Disruption of the PH and kinase domain interaction
was identified as a plausible cause of increased Akt1 phosphorylation and subsequent activity in
cancer [18].
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Here we quantified the ability of the PH domain to auto-inhibit Akt1 variants phosphorylated at
either or both key regulatory sites Thr308 and Ser473. We produced novel recombinant Akt1 variants
lacking the PH domain (∆PH-Akt1) that also contained programmed phosphorylation at each site
separately or with both sites phosphorylated. In the context of full-length phosphorylated Akt1
variants, we quantified the contribution of both regulatory phosphorylation sites to chemical inhibition
with the PH domain–dependent allosteric inhibitor Akti-1/2.

Figure 2. Simplified schematic of protein kinase B (Akt1) activation via phosphorylation of sites Thr308
and Ser473. The transition from Akt1’s inactive state (PH-in) to its fully active state (ppAkt1T308/S473 )
requires the release of pleckstrin homology (PH) domain–mediated auto-inhibition. This release occurs
when Akt1’s PH domain interacts with PIP3 (PH-out). In the PH-out conformation, Akt1 is more susceptible
to phosphorylation at Thr308 and Ser473 by phosphoinositide dependent kinase 1 (PDK1) and mechanistic
target of rapamycin complex 2 (mTORC2), respectively. Upon release from PIP3 , Akt1 distributes rapidly in
the cytosol and translocates to the nucleus to phosphorylate >100 cellular proteins [2,17].

2. Materials and Methods
2.1. Bacterial Strains and Plasmids
We designed a codon-optimized PH domain–deficient (∆PH) human AKT1 gene
(residues 109–480), which was synthesized by ATUM (Newark, CA, USA). The ∆PH-AKT1 gene
was subcloned (NcoI/NotI) into an isopropyl β-D-1-thiogalactopyranoside (IPTG)–inducible
T7lac promoter–driven pCDF-Duet1 vector with CloDF13-derived CDF replicon and
streptomycin/spectinomycin resistance (pCDF-Duet1-∆PHAkt1). The PDPK1 gene was purchased
from the Harvard PlasmidID repository service (plasmid ID: HsCD00001584; Boston, MA, USA)
and subcloned (KpnI/NdeI) into the second multicloning site (MCS) of pCDF-Duet-1. Full-length
pAkt1 variants were produced from pCDF-Duet1 plasmids as described previously [12]. The genetic
code expansion system for phosphoserine (pSer) is encoded on the pDS-pSer2 plasmid [12,19,20],
which contains 5 copies of tRNASep [21], phosphoseryl-tRNA synthetase (SepRS9), and elongation
factor Tu mutant (EFSep21) [22]. Incorporation of pSer also required site-directed mutagenesis of the
Ser473 codon to TAG in the ∆PH-akt1 constructs. Successful cloning was verified by DNA sequencing
at the London Regional Genomics Centre (London, ON, Canada) and Genewiz (Cambridge, MA,
USA).
2.2. Protein and Phosphoprotein Production
Recombinant Akt1 protein variants were expressed in BL21(DE3) (ThermoFisher Scientific,
Waltham, MA, USA) (Figure 1). The pDS-pSer2 plasmid [20] was used as before [12] to incorporate
pSer in response to a UAG codon at position 473 in ∆PHAkt1 and full-length Akt1 variants. To produce
both full-length and PH domain–deficient Akt1 variants containing pSer473 (Supplementary Table S1),
the pCDFDuet-1 Akt1–bearing plasmid was co-transformed with pDS-pSer2 into Escherichia coli
Bl21(DE3) and plated on Luria broth (LB) agar plates with 25 µg/mL kanamycin and 50 µg/mL
streptomycin. To produce pAkt1T308 variants, a pCDF-Duet1 plasmid containing both the Akt1 variant
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(MSC 2) and PDK1 (MSC 1) was transformed into E. coli BL21(DE3) and plated on LB agar plates
with 50 µg/mL streptomycin. To produce ppAkt1T308,S473 variants, a pCDF-Duet1 plasmid containing
both the Akt1 variant, MSC 2, with a TAG codon at position 473 and PDK1 variant, MSC 1 [12] was
co-transformed with pDS-pSer2 into E. coli Bl21(DE3) and plated on LB agar plates with 25 µg/mL
kanamycin and 50 µg/mL streptomycin.
In all cases, a single colony was used to inoculate 70 mL of LB (with 50 µg/mL streptomycin and,
if needed, 25 µg/mL kanamycin), which was grown, shaking, overnight at 37 ◦ C. From this starter culture,
a 10 mL inoculum was added to 1 L of LB with antibiotics (as above) and, for pSer473-containing variants
only, O-phospho-L-serine (Sigma Aldrich, Oakville, ON, Canada) was added to a final concentration of
2.5 mM. The cultures were grown at 37 ◦ C until OD600 = 0.6, at which point, for pSer473-containing variants
only, 2.5 mM of additional pSer was added to the culture. Protein expression was induced by adding
300 µM of IPTG at OD600 = 0.8. Cultures were then incubated at 16 ◦ C for 18 h. Cells were grown and
pelleted at 5000× g and stored at −80 ◦ C until further analysis. Akt1 protein variants were purified from
the cell pellets using Ni-nitrilotriacetic acid affinity column chromatography (see Supplementary Material,
affinity column chromatography description).
2.3. Parallel-Reaction Monitoring Mass Spectrometry of ppAkt1
The ppAkt1 protein produced as described above and the commercially available active Akt1
(Abcam, lot 1, Cambridge, MA, USA) were precipitated in ice-cold acetone/ethanol/acetic acid (50/50/0.1,
vol/vol/vol). The protein precipitate was resuspended in 8 M urea, then reduced in 5 mM dithiothreitol
(DTT) at 37 ◦ C for 1 h and alkylated in 14 mM iodoacetamide (IAA) in darkness at room temperature for
1 h. Unreacted IAA was neutralized by adding 5 mM DTT. The final protein concentration was determined
by Bradford assay. Glu-C digestion was performed at 37 ◦ C overnight with a Glu-C–to–protein ratio of
1:20 (w/w). The digest was desalted in C18 column (Phenomenex, Torance, CA, USA) according to the
manufacturer’s protocol and resuspended in mass spectrometry (MS)-grade water. A Q Exactive Hybrid
Quadrupole Orbitrap MS (Thermo Fisher Scientific, Waltham, MA, USA) was used to analyze the peptides.
Data were analyzed using Skyline software [23].
2.4. MALDI-TOF/TOF Mass Spectrometry Analysis
In-gel digestion was performed using MassPREP automated digester station (PerkinElmer,
Downers Grove, IL, USA). Gel pieces were de-stained using 50 mM ammonium bicarbonate and 50%
acetonitrile, which was followed by protein reduction using 10 mM DTT, alkylation using 55 mM IAA, and tryptic
digestion in 50 mM ammonium bicarbonate, pH 8. Peptides were extracted using a solution of 1% formic acid
and 2% acetonitrile and lyophilized. Prior to mass spectrometry analysis, dried peptide samples were re-dissolved
in a 10% acetonitrile and 0.1% trifluoroacetic acid solution. MALDI matrix, a–cyano–4–hydroxycinnamic acid,
was prepared as 5 mg/mL in 6 mM ammonium phosphate monobasic, 50% acetonitrile, 0.1% trifluoroacetic
acid and mixed with the sample at a 1:1 ratio (v/v). Mass spectrometry data (Figure S1) were obtained using an
AB Sciex 5800 MALDI TOF/TOF system (Framingham, MA, USA). Data acquisition and data processing were
done using a TOF/TOF Series Explorer a nd Data Explorer (both from AB Sciex, Boston, MA, USA), respectively.
The instrument was equipped with a 349 nm Nd:YLF OptiBeam On-Axis laser. The laser pulse rate was 400 Hz.
Reflectron positive mode was used. Reflectron mode was externally calibrated at 50 ppm mass tolerance and
internally at 10 ppm. Each mass spectrum was collected as a sum of 500 shots.
2.5. Akt1 Kinase Activity Assay
The activity of each Akt1 variant was characterized by performing kinase assays in the
presence of 200 µM substrate peptide CKRPRAASFAE (SignalChem, Vancouver, BC, Canada) derived
from the natural Akt1 substrate, glycogen synthase kinase (GSK-3β). Assays were performed in
3-(N-morpholino) propanesulfonic acid (MOPS, 25 mM, pH 7.0), β-glycerolphosphate (12.5 mM),
MgCl2 (25 mM), ethylene glycol-bis(β-aminoethyl ether)-N,N,N 0 ,N 0 -tetraacetic acid (EGTA, 5 mM,
pH 8.0), ethylenediaminetetraacetic acid (EDTA) (2 mM), ATP (0.02 mM), and 0.4 µCi (0.033 µM)
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γ-[32P]-ATP in a 30 µL reaction volume. Reactions were incubated at 37 ◦ C and time points were taken
over 30 min time courses. As previously [12], reactions were initiated by the addition of 18 pmol of the
indicated Akt1 variant to yield a final enzyme concentration of 600 nM and quenched by spotting on
P81 paper [24]. For highly active Akt1 variants, the level of Akt1 was titrated to identify a linear range
to accurately determine initial velocity (vo ) (Figure S2). For this reason, Akt1 activity was compared
based on the apparent catalytic rate (kapp ) = vo /[Akt1]. Samples from each reaction (5 µL) were spotted
on P81 paper at specified time points. Following washes with 1% phosphoric acid (3 × 10 min) and
95% ethanol (1 × 5 min), the P81 paper was air-dried. Incorporation of 32 P into the substrate peptide
was detected by exposing the P81 paper to a phosphor-imaging screen. The 32 P-peptide products
were imaged and quantitated using a Storm 860 Molecular Imager and ImageQuant TL software
(GE Healthcare, Mississauga, ON, Canada).
2.6. Kinase Inhibition Assay
A concentration gradient (0.001, 0.05, 0.5, 1, 5, 10 µM) of Akti-1/2 inhibitor VIII
(Sellekchem, Houston, TX, USA) [25] was selected to determine the concentration dependence of
Akt1 inhibition. Kinase inhibition assays were performed exactly as described above (Section 2.5) and
with the addition of dimethyl sulfoxide at 10% (vol/vol) (control) or the indicated concentration of
Akti-1/2 inhibitor. For each condition, initial velocity was determined over a time course of 10 min
with time points at 0, 2, 5, and 10 min (Figure S3). In the inhibition assays, following established
protocols [18], the inhibitor was preincubated with the enzyme for 5 min at 37 ◦ C before addition of ATP
and Akt1 substrate peptide to start the reaction. The time courses were used to determine the initial
velocity of each reaction. The fraction of enzyme inhibition was measured based on initial velocities
of uninhibited and inhibited reactions. From these data, half maximal inhibitory concentration (IC50 )
values were calculated using Sigma Plot (Systat Software, Inc., San Jose, CA, USA).
3. Results
3.1. Production of Recombinant Akt1 Variants
We recently established a method to produce full-length Akt1 variants with programmed
phosphorylations [12]. Here we applied this method to produced site-specifically phosphorylated
Akt1 variants lacking the auto-inhibitory PH domain. The approach combines in vivo enzymatic
phosphorylation with genetic code expansion to produce Akt1 variants containing either or both
pThr308 and pSer473 (Figure 1).
Using genetic code expansion [12,20], we incorporated pSer in response to a UAG stop codon
at position 473 in the relevant Akt1 constructs. Thr308 was site-specifically phosphorylated by
co-expression of the upstream kinase PDK1 in E. coli. We [12] and others [26] have demonstrated that
PDK1 is strictly specific in phosphorylating only the 308 site in Akt1. We used these methods in isolation
or in combination to produce the three physiologically relevant Akt1 variants pAkt1S473 , pAkt1T308 ,
and ppAkt1T308,S473 (Figure 1). We observed that the ∆PH-Akt1 variants were all more soluble and
were produced at 1.5- to 7-fold greater yield per liter of E. coli culture than the corresponding full-length
Akt1 variants (Table 1). As previously reported [12], we confirmed phosphorylation of the Thr308 site
(Figure 3C) and the Ser473 site (Figure S1) by mass spectrometry.
Table 1. Protein yields for Akt1 variants.
Protein Yields (µg/L Escherichia coli Culture)
Akt1 Variant

Full Length

∆PH Akt1

Akt1 (unphosphorylated)
pAkt1S473
pAkt1T308
ppAkt1T308,S473

46
100
37
45

330
150
235
224
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3.2. Recombinant Akt1 Produced in E. coli Versus Sf9 Cells
Earlier work established production of partially active and truncated Akt1 in E. coli, which
was unsuccessful at producing a sufficient amount of full-length Akt1 to determine activity [27].
Although we recently overcame these difficulties and developed a robust protocol to produce
full-length Akt1 from E. coli with programmed phosphorylation, studies in the intervening period
relied on insect Sf9 cell culture to produce recombinant Akt1 [28]. The ability to generate ppAkt1 from
insect cells, however, requires a complex and low-yield in vitro procedure to phosphorylate Akt with
two additional purified upstream kinases in the presence of lipid vesicles [28]. Protein production in
Sf9 cells failed to yeild Akt1 with site-specific or programmed phosphorylation. The resulting protein
was a mixture of singly and doubly phosphorylated species [29].
In order to benchmark the activity of the recombinant phosphorylated Akt1 protein we produced
in E. coli, we compared the activity of full-length ppAkt1 to active Akt1 purchased from Abcam.
The commercially available full-length Akt1 is made by a protocol similar to that established
previously [28], in which Akt1 protein production in Sf9 cells is followed by in vitro phosphorylation
of the purified Akt1 with purified PDK1. In testing an initial lot of active Akt1 (lot 1), we found that
the commercially available Akt1 enzyme was catalytically deficient by eight-fold (Table 2) compared
to the full-length ppAkt1 we produced (Figure 3A).
Table 2. Activity of Akt1 variants.
Akt1 Variant
Akt1 (unphosphorylated)
pAkt1S473
pAkt1T308
ppAkt1T308,S473
∆PHAkt1 (unphosphorylated)
∆PH pAkt1S473
∆PH pAkt1T308
∆PH ppAkt1T308,S473
Commercial Akt1 (Abcam)
Lot 1
Lot 2

Akt1 Amount
(pmol)

Initial Velocity
vo (fmol/min)

Apparent Catalytic Rate
kapp (fmol/min/pmol Akt1)

Activation
(Fold Increase)

Reference

18
18
1.8
1.8
18
18
0.18
0.18

0.6 ± 0.2
46 ± 5
22 ± 4
79 ± 11
1.4 ± 0.1
210 ± 20
370 ± 100
2300 ± 600

0.03 ± 0.01
2.6 ± 0.3
12 ± 2
44 ± 6
0.079 ± 0.006
12 ± 1
2100 ± 600
(13 ± 3) × 103

1.0 ± 0.3
85 ± 9
400 ± 70
1500 ± 200
2.7 ± 0.2
390 ± 40
6900 ± 1800
(4 ± 1) × 105

[12]
[12]
[12]
[12]
this study
this study
this study
this study

18
18

100 ± 20
2200 ± 700

6±1
120 ± 40

200 ± 30
4000 ± 1000

this study
this study

Parallel-reaction monitoring mass spectrometry (PRM-MS/MS) was used to determine the
identity of the residue at position 308 and the level of phosphorylation in ppAkt1 we produced
and in the purchased protein. Mass spectrometry revealed that the low activity of lot 1 enzyme
was attributable to the low level of phosphorylation at position 308 (peak intensity 1.3 × 101 ) and
a relatively high level of unphosphorylated Thr at position 308 (Figure 3B). In contrast, ppAkt1T308,S473
that we produced showed a high level (peak intensity 1.6 × 106 ) of Thr308 phosphorylation and
unphosphorylated Thr308 was not detected (Figure 3C). We then purchased a second lot of Akt1
enzyme (lot 2), and this enzyme displayed significantly more but highly variable activity compared
to lot 1 (Table 2). Presumably, the second lot was quantitatively phosphorylated during production.
In contrast to the method we developed for pAkt1 production in E. coli (Figure 1), the protocol to
generate active Akt1 relying on Sf9 cells and subsequent in vitro phosphorylation appears to lead to
a variable level of phosphorylation and activity in the resulting Akt1 preparations.
3.3. Impact of PH Domain Deletion on Differentially Phosphorylated Akt1
In order to determine the impact of the PH domain on each phospho-form of Akt1, we next
assayed the activity of specifically phosphorylated ∆PH-Akt1 variants using γ-[32P]-ATP and
a substrate peptide for Akt1 (CKRPRAASFAE) that was derived from GSK-3β, a well-established
Akt1 substrate [12,30]. In kinase assay conditions that we previously optimized [12] to measure
a wide range of Akt1 activity, we determined the apparent catalytic rate of each ∆PH-Akt1 variant
(unphosphorylated, pAkt1S473 , pAkt1T308 , ppAkt1T308,S473 ). We then compared the apparent catalytic
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rates to the measurements we made previously with full-length Akt1 and pAkt1 variants to ascertain
the relative impact of each phosphorylation state on auto-inhibition by the PH domain.

Figure 3. Activity of full-length ppAkt1 and commercially available active Akt1. (A) Kinase activity
assays over a 30 min time course show substantially reduced activity of commercial Akt1 (lot 1,
green squares) compared to full-length ppAkt1 (blue diamonds) produced in E. coli. Commercial Akt1
lot 2 (red circles) showed highly variable but similar activity to full-length ppAkt1. (B) Tryptic peptides
from commercial Akt1 and ppAkt1 were analyzed by parallel-reaction monitoring mass spectrometry
(PRM-MS). The purchased active Akt1 (lot 1) showed a low-intensity peak for phosphorylation at
Thr308 (green peak at a retention time of ~40 min) and high-intensity peak for non-phosphorylated
Thr308 (cyan peak, retention time of ~37 min). (C) PRM-MS analysis of ppAkt1T308,S473 showed
a high-intensity peak for phosphorylation at Thr308 (green peak at a retention time of 40 min) and the
non-phosphorylated Thr308 was undetectable.

As anticipated, all Akt1 variants lacking the PH domain were significantly more active than their
full-length counterparts (Table 2). Doubly phosphorylated ∆PH-Akt1 (ppAktT308,S473 ) showed the
highest activity among all three variants (Figure 4). The unphosphorylated ∆PH-Akt1 showed a basal
level of activity that was significantly higher (2.7 ± 0.3-fold) than the background activity we recorded
for full-length unphosphorylated Akt1 (Table 3). Although both unphosphorylated Akt1s would not
have sufficient activity to induce Akt1-dependent signaling in cells [2,12], it is interesting to note that
the auto-inhibitory effect of the PH domain is indeed measurable in the increased minimal activity of
unphosphorylated ∆PH-Akt1 (Figure 4B).
Compared to unphosphorylated ∆PH-Akt1, the most active doubly phosphorylated Akt1 variant
(∆PH-ppAktT308,S473 ) showed a 150,000-fold increase in apparent catalytic rate (Table 2, Figure 4).
Since rapid enzyme kinetics were observed with 18 pmol of enzyme with both of these variants
containing Thr308 phosphorylation, the enzyme concentrations were subsequently reduced by 10-fold
and 100-fold to obtain a highly accurate initial velocity with which to determine the apparent rate
(kapp = vo /[enzyme]) (Figure S2).
Table 3. Relative activity of full-length Akt1 versus variants lacking the PH domain (∆PH Akt1) *.
Akt1 Variant

Full-Length Akt1

∆PH-Akt1

Akt1 (unphosphorylated)
pAkt1S473
pAkt1T308
ppAkt1T308,S473

1.0 ± 0.3
1.0 ± 0.1
1.0 ± 0.2
1.0 ± 0.1

2.7 ± 0.2
4.6 ± 0.4
175 ± 50
295 ± 68

* The fold increase in kapp for each ∆PH-Akt1 enzyme variant was calculated by normalizing to the corresponding
full-length Akt1 variant kapp .

Interestingly, dual phosphorylation of ∆PH-Akt1 led to a 100-fold greater increase in activity
than that observed upon dual phosphorylation of the full-length enzyme, which was 1500-fold
more active than the unphosphorylated full-length enzyme. The data indicate that the PH domain
significantly dampens the catalytic activity endowed by phosphorylation at Thr308 and Ser473
(Figure 5). The ∆PH-Akt1 variant with a single phosphorylation at the Thr308 site was robustly active,
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2500-fold above the unphosphorylated ∆PH-Akt1, yet with 60-fold reduced activity compared to the
doubly phosphorylated enzyme ∆PH-ppAktT308/S473 (Table 2). Phosphorylation at the C-terminal
site Ser473 activated the enzyme 140-fold above the unphosphorylated control, but to a lesser extent
(18-fold) than ∆PH-pAkt1T308 . We previously observed a quantitatively similar pattern of activity with
the full-length Akt1 variants (Table 2, [12]).

Figure 4. Enzyme activity of ∆PH-Akt1 variants. (A) The activity of differentially phosphorylated
∆PH Akt1 variants with the GSK-3β substrate peptide was measured over a 30 min time course.
Akt1 phosphorylated at 308 and 473 (∆PH-ppAktS473,T308 , blue diamonds) showed maximal activity
compared to unphosphorylated ∆PH-Akt1 (gray circles) and singly phosphorylated Akt1 variants
∆PH-pAkt1T308 (black diamonds) and ∆PH-pAkt1S473 (pink triangles). (B) The basal activity of
unphosphorylated ∆PH-Akt1 (gray circles) was compared to full-length unphosphorylated Akt1
(green triangles). All reported values represent the mean of triplicate experiments, with error bars
indicating one standard deviation.

We found that the PH domain exerts an auto-inhibitory effect, the strength of which depends
on the phosphorylation status of the Akt1 enzyme. We compared apparent catalytic rates, kapp ,
(Figure 5A) and normalized relative catalytic rates (Figure 5B) between the full-length [12] and
PH domain–deficient Akt1 variants. In the context of a single phosphorylation at Ser473, the PH
domain is associated with an approximately five-fold reduction in activity (Table 3, Figure 5).
In the singly phosphorylated pAkt1T308 enzyme, the auto-inhibition was far stronger (175-fold).
The two phosphorylations together led to a super-additive inhibitory effect (295-fold) in the doubly
phosphorylated enzyme (Figure 5).

Figure 5. Impact of PH domain on the activity of differentially phosphorylated Akt1. (A) Apparent
catalytic rates (kapp ) and (B) normalized kapp values of full-length Akt1 variants (blue) and ∆PH-Akt1
variants (red) are shown. Error bars represent one standard deviation of triplicate measurements.
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3.4. Chemical Inhibition of Phosphorylated Akt1 Variants
Given the differential impact of Akt1 phosphorylation on auto-inhibition, we next identified
phosphorylation dependence in the interaction between Akt1 and a clinically relevant drug scaffold,
Akti-1/2 inhibitor VIII. Several classes of chemical inhibitors were developed to repress aberrant Akt1
activity in cancer cells [10]. Early Akt1 inhibitors focused on ATP competitive compounds [31], yet these
molecules suffered from significant cross-reactivity with other AGC family kinases [32]. For this reason,
subsequent efforts focused on allosteric Akt1 inhibitors. Akti-1/2 is an allosteric inhibitor that binds
Akt1 in a cleft between the kinase and PH domains, locking the enzyme in a noncatalytic conformation
(Figure 6). Biochemical data with different Akt1 preparations has provided estimates of IC50 of Akt1
for the Akti-1/2 inhibitor ranging from 58 nM to 2.7 µM [24,33,34] (Table 4). We suspected that this
range of values resulted from preparations of Akt1 with various levels of phosphorylation, with less
active Akt1 preparations leading to an underestimate of IC50 . In addition, previous studies were
unable to isolate the contribution of each regulatory phosphorylation site to inhibition by Akti-1/2.

Figure 6. Structure of Akt1 in active and inhibitor bound forms. (A) Structure of ∆PH-pAkt1Thr308
Ser473Asp (PDB 1O6K [35]) is shown in complex with ATP analog (ANP-PNP) and substrate peptide
(purple). (B) Structure of the full-length Akt1 (unphosphorylated) is shown in complex with the
Akti-1/2 inhibitor VIII (PDB 1O96 [36]) binding in the cleft between the kinase domain (green) and the
N-terminal PH domain (red).

We conducted Akt1 inhibition assays using Akti-1/2 concentrations varying from 0.01 to 10 µM.
All three full-length phosphorylated Akt1 variants showed concentration-responsive enzyme inhibition
(Figure 7, Figures S3–S6). Akti-1/2 was most potent (IC50 = 300 nM) when only the Thr308 site was
phosphorylated (Table 4). Interestingly, at the lower concentrations of Akti-1/2 (0.001, 0.05, 0.5 µM),
the compound was not effective at inhibiting the activity of pAkt1S473 . Akt1 phosphorylated at the
C-terminal Ser473 site was overall more resistant to inhibitor VIII inhibition, resulting in an IC50
value of 1.3 µM. In a surprising finding, the doubly phosphorylated enzyme had an indistinguishable
IC50 from the pAkt1S473 enzyme. Together the data indicate that Ser473 phosphorylation provides
a four-fold increase in resistance to the Akti-1/2 inhibitor even in the presence of phosphorylation at
Thr308. This is the first report demonstrating phosphorylation dependence in the interaction between
Akt1 and an inhibitor.
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Table 4. Akti-1/2 inhibitor half maximal inhibitory concentration (IC50 ) for pAkt1 variants.
Akt1 Variant

Inhibitor Type

IC50 (µM)

Expression System

Reference

ppAkt1T308,S473

Akti-1/2 inhibitor VIII
Akti-1/2 inhibitor VIII
Akti-1/2 inhibitor VIII
Akti-1/2 inhibitor VIII
Akti-1/2 inhibitor VIII
Akti-1/2 inhibitor
Akti-1 inhibitor

1.2 ± 0.3
0.3 ± 0.1
1.3 ± 0.1
0.058
0.1
2.7
4.6

E. coli
E. coli
E. coli
Drosophila S2 cells
HEK 293 cells
Drosophila S2 cells
Drosophila S2 cells

this study
this study
this study
[25]
[33]
[34]
[34]

pAkt1T308
pAkt1S473
active
active
active
active

Figure 7. Chemical inhibition of full-length phosphorylated Akt1 variants. Inhibition of (A) pAkt1S473 ,
(B) pAkt1T308 , and (C) ppAkt1T308,S473 with varying concentrations (0.001, 0.05, 0.5, 1, 5, 10 µM) of
Akti-1/2 inhibitor VIII. The resulting IC50 values are in Table 4.

4. Discussion
Akt1 is a prime target for therapeutic intervention due to its involvement in regulating a multitude
of cellular pathways [37,38]. Aberrant Akt function has been linked to cancers and a variety of
human diseases related to metabolic regulation, immune function, and neurological development [2].
The broad range of cellular processes governed by Akt, therefore, presents an opportunity for
single-target therapeutic intervention in a variety of conditions. To capitalize on this opportunity,
compounds that selectively attenuate Akt1 activity rather than global kinase inactivation are required.
This need is reflected in clinical trials showing that nonspecific Akt inhibition in cancer therapy,
due to inadvertent off-targeting of closely related kinases or multiple Akt isozymes, can result
in detrimental side effects including liver damage and metabolic disorders [39–42]. Accordingly,
the development of small molecule inhibitors for Akt reflects this sentiment of engineering greater
target specificity [10]. From the earliest ATP-competitive inhibitors that unintentionally inhibited
related AGC kinases, to more recent allosteric inhibitors that preferentially target Akt or even a subset of
Akt isozymes, the continued pursuit for Akt1 inhibitor specificity requires an expanded understanding
of the molecular basis of Akt1 activation and inhibition.
Previous work was unable to uncover the role of each regulatory site (Thr308 and Ser473) in the inhibition
kinetics of Akt1. Given this critical knowledge gap, we investigated the role of Akt1 phosphorylation status
on the auto-inhibitory effect of the PH domain and on allosteric inhibition by Akti-1/2.
4.1. Phosphorylation-Dependent Auto-Inhibition of Akt1
The N-terminal PH domain is shared among all three Akt isozymes and its direct function
is to mediate protein–lipid interactions. It is well documented that PH domain binding to a lipid
second messenger PIP3 in cell membranes releases the inhibitory effect of the PH domain [2]. Here,
we produced differentially phosphorylated Akt1 variants with and without the PH domain in E. coli
using genetic code expansion to incorporate pSer473, and the upstream Thr308 kinase PDK1 was
co-expressed in E. coli, leading to quantitative phosphorylation of the recombinant Akt1 protein.
Compared to unphosphorylated Akt1, all phosphorylated variants showed increased enzyme activity.
Previously, live cell imaging studies revealed that, once phosphorylated, Akt1 favors a PH-out
conformation that increases Akt1 activity in the downstream phosphorylation of substrate proteins in
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both the cytoplasm and the nucleus. In addition, binding of Akt1 to PIP3 in the plasma membrane
further releases the auto-inhibitory effect of the PH domain [43,44]. Although phosphorylation
of the kinase domain at Thr308 is known to reduce the PH domain’s affinity for the kinase
domain [42], the contribution of Thr308 and Ser473 phosphorylation to auto-inhibition by the PH
domain was unknown.
We quantitated the release of PH domain–mediated inhibition corresponding to each
phosphorylation site and both sites in combination. Our data revealed that the magnitude of the
auto-inhibitory effect of the PH domain was sensitively dependent on the phosphorylation status
of Akt1. In comparison to the activity of full-length Akt1 phospho-variants, deletion of the PH
domain significantly increased activity. In comparison to singly phosphorylated Akt1 variants,
the auto-inhibitory effect of the PH domain was strongest (295-fold) in the most active and doubly
phosphorylated Akt1 variant. Interestingly, the doubly phosphorylated Akt1 displayed increased
activity upon PH domain deletion that was greater than the sum of the effects observed for the singly
phosphorylated Akt1 variants. The data suggest a novel finding that the PH domain dampens the
activity of Akt1 variants in a phosphorylation-dependent manner.
The combination of phosphorylation and PH domain release regulates the kinase activity of
Akt1 over a 400,000-fold range. The data indicate the degree to which the unphosphorylated PH-in
conformation of Akt1 is suppressed in comparison to the PH-out doubly phosphorylated version
of the enzyme that exists at the plasma membrane in living cells. Recent in vitro biochemical work
suggested that association with PIP3 -containing lipid vesicles stimulated the activity of a full-length
Akt1 protein by seven-fold [44]. The authors suggested that this may be an underestimate due to low
levels of phosphorylation (10% pThr308, 1% pSer473) in their Akt1 prepared from Sf9 cells. Our data
suggest that release of the PH domain in the context of doubly phosphorylated Akt1 would lead to
a maximal activity increase of 300-fold; a PH domain–dependent reduction lower than this value
would indicate that there may be significant interaction between the Akt1 kinase and PH domains
even in the PIP3 -bound state at the plasma membrane.
Indeed, a recent debate in the literature [45] is under way to explain how Akt1 activity can be
maintained far from the membrane. Recent findings suggest that Akt1 is dephosphorylated on a time
scale of ~10 min following dissociation from PIP3 on the plasma membrane [46]. Multiple nuclear
substrates of Akt1 are, however, known to be phosphorylated much more rapidly, on a time
scale of seconds [47]. Although the authors suggested that all or perhaps most of the active
Akt1 is membrane-associated [46], this finding disputes several independent studies identifying
many cytosolic and nuclear targets of Akt1-dependent phosphorylation. Multiple studies clearly
identified both phospho-Akt1 (e.g., [47–49]) and directly measured Akt1 activity in the nucleus [17].
Using a fluorescent reporter that quantifies Akt1 activity in live cells in real time, Kunkel and Newton
observed Akt1 activity distributed in both the cytoplasm and nucleus on a time scale of seconds
to minutes following growth factor stimulation. Their data further show similar levels of Akt1
activity in the nucleus and cytoplasm, with a delay in the peak activity in the nucleus of ~2 min.
Additional experiments confirmed that this lag is related to the time it takes for active Akt1 to
translocate from the plasma membrane to the nucleus [17]. In light of our data and these findings,
membrane-associated Akt1 is likely significantly more active than doubly phosphorylated Akt1 found
in the nucleus and cytosol. Phosphorylated Akt1, nevertheless, does persist away from the membrane,
retaining significant activity in comparison to unphosphorylated Akt1.
4.2. Phosphorylation-Dependent Chemical Inhibition of Akt1
Posttranslational modifications, of which phosphorylation is the most common, are ubiquitous
mechanisms that cells use to tune the activity of individual proteins and increase the functional
diversity of the proteome. Phosphorylation can have a significant impact on the activity of proteins
(kinases are a prime example), and the phosphorylation status of a protein target can accordingly
impact the ability of small molecules to inhibit enzyme activity. In the experiments presented
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here, we determined precisely how the phosphorylation status of Akt1 influences the repression
of kinase activity by chemical inhibition. We investigated the Akt-specific allosteric inhibitor Akti-1/2.
Based on the results of our assays, the phosphorylation status of Akt1 can indeed influence the
degree to which Akti-1/2 is able to act on Akt1. Akti-1/2 was most effective at inhibiting pAkt1T308 ,
whereas phosphorylation at position Ser473 in either pAktS473 or ppAktT308/S473 reduced the relative
effectiveness of the inhibitor by four-fold.
Ser473 phosphorylation appears to act as a built-in mechanism of drug resistance for Akt1.
It is well established that hyperphosphorylation of Akt1 at both regulatory sites is linked to poor
prognosis and therapeutic resistance [3–6,50]. The accepted model for Akti-1/2 activity suggests that
the compound locks Akt1 into the auto-inhibited or PH-in conformation and prevents Akt1 from
binding PIP3 in the plasma membrane, inhibiting phosphorylation at Thr308 and Ser473 [51]. Our data
also suggest that, although limited by Ser473 phosphorylation, Akti-1/2 has significant activity in
inhibiting the pre-phosphorylated Akt1 variants that the inhibitor initially encounters in the cell.
Studies in cell culture and mouse models show that the short-term impact of Akti-1/2 treatment is that
pThr308 and pSer473 levels are depleted within hours. A related allosteric Akt inhibitor, and the most
clinically promising [52] compound, MK-2206 significantly reduces Ser473 phosphorylation after 10 h
in mouse models with patient-derived xenografts of endometrial tumors [53].
Surprisingly, breast cancer cells (BT474) treated with Akti-1/2 (1 µM) showed a rebound effect in
Akt1 phosphorylation status following Akti-1/2 treatment. These cells have amplified HER2 genes and
constitutively activate the PI3K/Akt signaling cascade. In short-term experiments (minutes to hours),
Akt1 phosphorylation reduced in response to inhibitor treatment, but at longer times (2–3 days) Akt1
phosphorylation status returned to stimulated levels in these cancer cells. In this longer time frame,
phosphorylation of the downstream Akt1 target S6K was not restored, but PRAS40 phosphorylation
was partially restored concomitant with increased Akt1 phospho-status. The study provided evidence
that Akti-1/2 ultimately induces the expression and activation of receptor tyrosine kinases EGFR,
HER3, and HER4, which in turn reactivate Akt1 [54]. Interestingly, in mouse models a similar rebound
in Ser473 phosphorylation following treatment with MK-2206 was observed on time courses of 5 to
20 days [55]. In these cases, Ser473 phosphorylation may provide the tumor cell with a means to
reduce the effectiveness of Akt1 inhibitors. The data suggest a need to develop an inhibitor that is
more effective against the most active and doubly phosphorylated form of Akt1.
4.3. Synthetic Biology Approach to Generate Active Akt1
In our current study and previous work [12,19–21], we demonstrated that genetic code expansion
with pSer in E. coli provides a simple route to produce designer phosphoproteins. Here, we produced
differentially phosphorylated Akt1 variants with and without the PH domain in E. coli using genetic
code expansion and enzymatic phosphorylation in E. coli. We found that the variants lacking the
PH domain were produced at significantly higher yield compared to the full-length Akt1 protein.
The ability to produce recombinant Akt1 protein with programmed phosphorylation(s) was essential
for our investigation into the role of each phospho-site in Akt1 inhibition.
In agreement with our previous work [12], we found that the system we developed to produce
Akt1 with either or both regulatory phosphorylation sites (Figure 1) leads to a consistently active
Akt1 variant with indistinguishable batch-to-batch variability. This is in contrast to the commercially
available Akt1 produced using the Sf9 cell system followed by in vitro PDK1 phosphorylation of
Thr308 [28]. We observed vast batch-to-batch variability of enzyme activity in the commercially
available Akt1, which warrants cautious attention in its experimental use. Previous work also
established that Akt1 produced in Sf9 cells leads to a mixture of singly and doubly phosphorylated Akt1
variants [29], at times leading to low stoichiometry of phosphorylation [44] (Figure 3B). Our approach
consistently results in site-specifically phosphorylated and active Akt1 variants that provide a reliable
and consistent source of protein for biochemical studies and applications in inhibitor screening.
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